TABLE 1.
Baseline characteristics of patients
| Characteristic | Value for the characteristic (n = 24)a |
|---|---|
| No. of male patients (%) | 19 (79) |
| Age (yr [SD]) | 47.7 (9.71) |
| Race (no. of patients [%]) | |
| White | 20 (83) |
| Other | 4 (17) |
| Weight (kg [SD]) | 78.0 (12.33) |
| Body mass index (kg/m2 [SD]) | 25.3 (3.00) |
| Median HCV RNA level (IU/ml [range]) | 6.56 (5.78–7.27) |
| HCV subtype (no. of patients [%])b | |
| 1a | 8 (33) |
| 1b | 16 (67) |
| IL28B genotype (no. of patients [%])c | |
| CC | 1/23 (4) |
| CT | 14/23 (61) |
| TT | 8/23 (35) |
| Median ALT (IU/ml [range])d | 79.5 (24–275) |
a
Participants received ritonavir-boosted danoprevir (DNVr) 100/100 mg q12h plus PegIFN alfa-2a–RBV. Data presented as mean (standard deviation) unless stated otherwise.
b
The predominance of HCV G1b-infected versus G1a-infected patients was due to a protocol amendment, whereby enrollment of G1a patients was stopped and restricted to G1b patients because of high rates of virologic breakthrough.
c
Twenty-three of 24 patients consented to IL28B genotyping.
d
ALT, alanine aminotransferase.